Europe Continuous Glucose Monitoring (CGM) Devices Market Growth Analysis, Dynamics, Key Players and

Author : Sneha Garg | Published On : 08 Jun 2026

According to a new report from Intel Market Research, the Europe Continuous Glucose Monitoring (CGM) Devices market was valued at USD 1.96 billion in 2025 and is projected to reach USD 4.76 billion by 2034, growing at a robust CAGR of 10·3% during the forecast period (2026–2034). This growth is propelled by the accelerating prevalence of diabetes across Europe, continuous technological innovation in sensor design, and increasingly favourable reimbursement frameworks in key European economies.

Continuous Glucose Monitoring (CGM) devices are advanced medical technologies designed to provide real‑time glucose readings for individuals managing diabetes. These wearable systems consist of a small sensor inserted under the skin, a transmitter, and a receiver or smartphone application that continuously displays glucose levels throughout the day and night. Key components include sensors that measure interstitial glucose, wireless transmitters, and software algorithms that analyse patterns to support clinical decision‑making.

📥 Download FREE Sample Report:
Europe Continuous Glucose Monitoring (CGM) Devices Market - View in Detailed Research Report

What is CGM?

CGM technology enables continuous measurement of glucose concentrations in the interstitial fluid, offering a dynamic picture of glycaemic trends that cannot be captured by intermittent finger‑stick testing. By delivering alerts for hypo‑ and hyper‑glycaemic excursions, CGM empowers patients and clinicians to intervene promptly, optimise insulin therapy, and ultimately improve long‑term outcomes. The technology has evolved from bulky, calibration‑intensive prototypes to sleek, factory‑calibrated systems that can be worn for up to 14 days without the need for finger‑stick verification.

This report delivers an exhaustive view of the Europe CGM market, covering macro‑level market sizing, granular segmentation, competitive dynamics, emerging trends, and strategic recommendations for stakeholders. It is crafted to help manufacturers, investors, regulators, and healthcare providers make informed decisions in a rapidly evolving landscape.

Key Market Drivers

1. Rising Diabetes Prevalence Across Europe
The International Diabetes Federation estimates that more than 61 million adults in Europe were living with diabetes in 2023. This expanding patient pool, coupled with growing clinical consensus that CGM improves glycaemic control for both Type 1 and high‑risk Type 2 patients, fuels demand for continuous monitoring solutions.

2. Technological Advancements and User‑Centred Design
Factory‑calibrated sensors, Bluetooth‑enabled transmitters, and AI‑driven trend analytics have reduced the burden of calibrations and enhanced user experience. Miniaturised form factors, longer wear times, and seamless integration with insulin‑pump and digital health platforms make CGM an attractive therapeutic adjunct.

➤ The market is projected to exceed €2.5 billion by 2028, growing at a CAGR of 12%.

3. Expanding Reimbursement and Regulatory Support
Numerous EU member states have introduced or broadened reimbursement schemes for CGM, aligning out‑of‑pocket costs with demonstrated clinical benefits. Simultaneously, the harmonisation of EU medical‑device directives streamlines approvals, encouraging manufacturers to launch innovative products across the region.

Market Challenges

High Initial Acquisition Cost
Even with expanding reimbursement, the upfront price of CGM kits remains a barrier in Southern European markets where public funding is limited. Cost‑sensitivity can slow adoption among price‑conscious consumers.

Regulatory Complexity
Diverse national regulations on device classification, data privacy (GDPR), and health‑technology assessment generate additional compliance burdens, potentially delaying market entry for novel technologies.

Market Restraints

Limited Reimbursement Coverage in Certain Countries
While Western Europe enjoys mature reimbursement pathways, several Central and Eastern European health systems still categorise CGM as a premium product, limiting diffusion.

Patient Training and Sensor Adherence
Effective use of CGM requires regular sensor replacement and proper interpretation of trend data. Gaps in training programs can lead to poor adherence, reducing clinical value.

Market Opportunities

Integration with Telehealth and Digital Health Platforms
The rapid adoption of telemedicine across Europe creates a natural conduit for CGM data sharing, enabling remote monitoring, real‑time therapy adjustments, and data‑driven population health management.

Emergence of Miniaturised Implantable Sensors
Implantable CGM sensors with multi‑year lifespans are entering early‑stage pilots in Scandinavia, promising to address cost and adherence concerns by minimising sensor‑change frequency.

Regional Market Insights

• Western Europe: Germany, France, the United Kingdom, and the Benelux region lead adoption due to robust reimbursement, high physician awareness, and strong digital‑health infrastructure.
• Southern Europe: Italy, Spain, and Greece exhibit slower growth, constrained by limited public funding and higher out‑of‑pocket costs.
• Scandinavian & Central Europe: Sweden, Norway, Denmark, and Poland display strong interest in AI‑driven analytics and closed‑loop insulin delivery pilots.
• Emerging Markets: Romania, Bulgaria, and the Baltic states present untapped potential as national health systems begin to modernise diabetes care pathways.

Market Segmentation

By Type

• Integrated CGM
• Standalone CGM

By Application

• Diabetes Management
• Health & Wellness
• Clinical Research
• Others

By End User

• Hospitals & Clinics
• Home Care Patients
• Specialty Diabetes Centers

By Technology

• Enzyme‑Based Sensors
• Fluorescence‑Based Sensors
• Microneedle Sensors

By Market Opportunity

• Remote Monitoring Platforms
• Fitness & Lifestyle Consumers
• Pediatric Diabetes Care

Segment Analysis:

 

Segment Category	Sub‑Segments	Key Insights
By Type	Integrated CGM Standalone CGM	Integrated CGM is the leading segment in Europe because it merges continuous glucose data with insulin‑pump therapy, creating a seamless closed‑loop experience. Provides automated insulin adjustments, reducing wearer burden. Facilitates data sharing with clinicians through secure cloud platforms. Creates high entry barriers for competitors lacking interoperable ecosystems.
By Application	Diabetes Management Health & Wellness Clinical Research Others	Diabetes Management dominates European deployment, yet the health‑and‑wellness niche is gaining momentum as athletes and wellness‑focused consumers adopt CGM for performance monitoring. Clinical pathways encourage early adoption for Type 1 and Type 2 patients. Fitness‑driven users seek real‑time glucose trends to optimise training and recovery. Research institutions leverage CGM data to study metabolic responses across diverse populations.
By End User	Hospitals & Clinics Home Care Patients Specialty Diabetes Centers	Home Care Patients emerge as the most dynamic end‑user segment across Europe, driven by reimbursement schemes that favour outpatient monitoring and by patient preferences for unobtrusive wearables. Patients value the convenience of self‑managed data without frequent clinic visits. Remote monitoring programmes enable clinicians to intervene proactively. Growing familiarity with smartphone‑linked CGM apps accelerates home adoption.
By Technology	Enzyme‑Based Sensors Fluorescence‑Based Sensors Microneedle Sensors	Enzyme‑Based Sensors retain primacy in Europe because they combine proven accuracy with established regulatory pathways. Well‑documented performance in varied climatic conditions across the continent. Compatibility with existing payer reimbursement frameworks. Continuous improvements in calibration reduce user workload.
By Market Opportunity	Remote Monitoring Platforms Fitness & Lifestyle Consumers Pediatric Diabetes Care	Remote Monitoring Platforms are the fastest‑growing opportunity as European health systems integrate CGM data into telehealth workflows. Enables real‑time clinician alerts, reducing emergency admissions. Supports cross‑border data exchange compliant with GDPR. Aligns with national strategies to digitalise chronic disease management.

COMPETITIVE LANDSCAPE

 

 

Key Industry Players

 

Europe CGM Devices Market – Competitive Overview

In the European Continuous Glucose Monitoring (CGM) Devices market, Abbott Laboratories dominates with its FreeStyle Libre system, which enjoys widespread reimbursement and a robust distribution network across the EU and UK. Dexcom follows closely, leveraging its G6 and G7 sensors that have secured CE‑Mark certification in multiple member states. Medtronic, with the Guardian sensor family, remains a strong contender because of its integrated insulin‑pump solutions that are favoured by hospitals and specialty clinics. These three manufacturers control a significant share of the market, benefiting from established regulatory pathways, extensive clinical data, and strong brand recognition.

Beyond the leading tier, a diverse set of niche players enriches the competitive landscape. Senseonics offers the long‑lasting Eversense implantable sensor, approved for use in several European countries, while Roche is entering the space through strategic partnerships that extend its diagnostic expertise to CGM. Emerging innovators such as Biolinq, Nemaura (SugarBEAT), Glytec, GlycoTrack (Integrity Applications), and Valeritas are expanding market depth with novel sensor technologies, non‑invasive approaches, or cloud‑based analytics. All listed firms maintain active operations in Europe, either through direct sales, local subsidiaries, or authorized distributors, confirming their relevance for a comprehensive competitive assessment.

List of Key Continuous Glucose Monitoring (CGM) Devices Companies Profiled

• Abbott Laboratories

• Dexcom, Inc.

• Medtronic plc

• Senseonics, Inc.

• Roche Diagnostics

• Biolinq

• Nemaura Medical

• Glytec Ltd.

• GlycoTrack (Integrity Applications)

• Valeritas, Inc.

• Insulet Corporation

• Novo Nordisk A/S (partnered CGM initiatives)

Report Deliverables

• Europe and regional market forecasts from 2025 to 2034
• Strategic insights into pipeline developments, clinical trials, and regulatory approvals
• Market share analysis and SWOT assessments for major players
• Pricing trends, reimbursement dynamics, and payer landscape
• Comprehensive segmentation by type, application, end‑user, technology and opportunity

📘 Get Full Report Here:
Europe Continuous Glucose Monitoring (CGM) Devices Market - View Detailed Research Report

FREQUENTLY ASKED QUESTIONS

About Intel Market Research

Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:

• Real-time competitive benchmarking
• Global clinical trial pipeline monitoring
• Country-specific regulatory and pricing analysis
• Over 500+ healthcare reports annually

Trusted by Fortune 500 companies, our insights empower decision‑makers to drive innovation with confidence.

🌐 Website: https://www.intelmarketresearch.com
📞 Asia‑Pacific: +91 9169164321
🔗 LinkedIn: Follow Us